An imaging test could safely halve the number of people who need a biopsy for suspected prostate cancer following inconclusive or reassuring results from an MRI scan, new research has found. Findings ...

Detection of prostate cancer and its recurrence is challenging as it is a heterogeneous disease and methods such as PET imaging and measurement of biochemical response using prostate specific membrane ...

Commonwealth Health Wilkes-Barre General Hospital is the first institution in our area to offer the new FDA approved and NCCN-indicated, prostate specific membrane antigen (PSMA) imaging agent to ...

Daniel Oguna, a PET CT technologist prepares a patient for a scan procedure at Aga Khan University Hospital, Nairobi. [Photo: Standard] The latest and most advanced scan for evaluation of patients ...

Getty Images Use of 68 Ga-PSMA PET/CT may avoid unnecessary biopsies in some men with equivocal PI-RADS 3 lesions on mpMRI. Gallium 68-labelled prostate-specific membrane antigen positron emission ...

Getty Images In patients with high-risk prostate cancer, negative PSMA PET/CT does not permit PLND avoidance, investigators cautioned. Findings from positron emission tomography-computed tomography ...

Continuous advances in artificial intelligence promise to shake up medical care in all kinds of exciting ways, with the ability to rapidly scan medical images and spot signs of disease far more ...

Prostate-specific membrane antigen (PSMA)-PET/CT imaging identified metastatic prostate cancer in almost half of high-risk cases missed by conventional imaging, a retrospective analysis showed.